Biosimilar monoclonal antibodies in China: A patent review

References

• Ecker DM, Jones SD, Levine HL, et al. The therapeutic monoclonal antibody market. MAbs. 2015;7(1):9–14.
   PubMed Web of Science ®Google Scholar
• Elgundi Z, Reslan M, Cruz E, et al. The state-of-play and future of antibody therapeutics. Adv Drug Deliv Rev. 2017;122:2–19.
   PubMed Web of Science ®Google Scholar
• Lu RM, Hwang Y-C, Liu I-J, et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27(1):1.
   PubMed Web of Science ®Google Scholar
• Ishii-Watabe A, Kuwabara T. Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies. Drug Metab Pharmacokinet. 2019;34(1):64–70.
   PubMed Web of Science ®Google Scholar
• FDA. FDA-approved biosimilar products. 2022.https://www.fda.gov/drugs/biosimilars/biosimilar-product-information
   Google Scholar
• EMA Medicines . 2022May 18. https://www.ema.europa.eu/en/medicines/search_api_aggregation_ema_medicine_types/field_ema_med_biosimilar/ema_group_types/ema_medicine
   Google Scholar
• Yang J, Yu S, Yang Z, et al. Efficacy and safety of anti-cancer biosimilars compared to reference biologics in oncology: a systematic review and meta-analysis of randomized controlled trials. BioDrugs. 2019;33(4):357–371.
   PubMed Web of Science ®Google Scholar
• Berg T, Jensen M-B, Jakobsen EH, et al. Neoadjuvant chemotherapy and HER2 dual blockade including biosimilar trastuzumab (SB3) for HER2-positive early breast cancer: population based real world data from the Danish Breast Cancer Group (DBCG). Breast. 2020;54:242–247.
   PubMed Web of Science ®Google Scholar
• Egeberg A, Girolomoni G, Feldman SR, et al. Real world SB4 (Etanercept Biosimilar) use in patients with psoriasis: data from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Drugs Dermatol. 2020;19(3):316–318.
   PubMed Web of Science ®Google Scholar
• Lee K, Ha JY, Jung AR, et al. The clinical outcomes of rituximab biosimilar CT-P10 (Truxima ®) with CHOP as first-line treatment for patients with diffuse large B-cell lymphoma: real-world experience. Leuk Lymphoma. 2020;61(7):1575–1583.
   PubMed Web of Science ®Google Scholar
• Bae SJ, Kim JH, Ahn SG, et al. Real-world clinical outcomes of biosimilar trastuzumab (CT-P6) in HER2-positive early-stage and metastatic breast cancer. Front Oncol. 2021;11:689587.
   PubMed Web of Science ®Google Scholar
• Melville AR, Md Yusof MY, Fitton J, et al. Real-world experience of effectiveness of non-medical switch from originator to biosimilar rituximab in rheumatoid arthritis. Rheumatology (Oxford). 2021;60(8):3679–3688.
   PubMed Web of Science ®Google Scholar
• Rhodes W, DeClue RW, Accortt NA, et al. Real-world use of bevacizumab-awwb, a bevacizumab biosimilar, in US patients with metastatic colorectal cancer. Future Oncol. 2021;17(36):5119–5127.
   PubMed Web of Science ®Google Scholar
• Shelbaya A. Real-world use and acceptance of biosimilar monoclonal antibodies of rituximab in oncology practice in the .Future Oncol. 2021
   Google Scholar
• Henlius. Company News. 2022.https://www.henlius.com/News.html
   Google Scholar
• NMPA. The state food and drug administration issued technical guidelines for the development and evaluation of biosimilar drugs. May 11.https://www.nmpa.gov.cn/directory/web/nmpa/yaopin/ypjgdt/20150303155101860.html
   Google Scholar
• Biosimilars FDA. 2021May 7.https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars
   Google Scholar
• FDA. Biosimilar and interchangeable products. 2021.https://www.fda.gov/drugs/biosimilars/biosimilar-and-interchangeable-products
   Google Scholar
• FDA. 2021. Biosimilar Development. Review, and Approval https://www.fda.gov/drugs/biosimilars/biosimilar-development-review-and-approval
   Google Scholar
• CDE of NMPA. Technical guidelines for the evaluation of similarities of biosimilars and the extrapolation of indications. 2021 Accessed 5 Mar 2022.https://www.cde.org.cn/main/news/viewInfoCommon/d92c6507a57bee9ccfc5baa1ee87fda9
   Google Scholar
• CDE of NMPA. Technical guidelines for clinical pharmacological research of biosimilars. 2022 Accessed 5 Mar 2022.https://www.cde.org.cn/main/news/viewInfoCommon/58b06d54af4f19d02a17e4d4d8d374f7
   Google Scholar
• Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol. 2002;2(5):364–371.
   PubMed Web of Science ®Google Scholar
• Torres-Acosta N, O’Keefe JH, O’Keefe EL, et al. Therapeutic potential of tnf-α inhibition for alzheimer’s disease prevention. J Alzheimers Dis. 2020;78(2):619–626.
   PubMed Web of Science ®Google Scholar
• van Schie Ka, van Schie KA, Hart MH, et al. The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Ann Rheum Dis. 2015;74(1):311–314.
   PubMed Web of Science ®Google Scholar
• Su J, Li M, He L, et al. Comparison of the efficacy and safety of adalimumab (humira) and the adalimumab biosimilar candidate (HS016) in Chinese patients with active ankylosing spondylitis: a multicenter, randomized, double-blind, parallel, phase iii clinical trial. BioDrugs. 2020;34(3):381–393.
   PubMed Web of Science ®Google Scholar
• Su J, Li M, He L, et al. Changes in efficacy indicators for adalimumab biosimilar candidate (Hs016) for the treatment of active ankylosing spondylitis at various time points. Front Pharmacol. 2020;11:606497.
   PubMed Web of Science ®Google Scholar
• Cao G, Yu J, Wu J, et al. A randomized, double-blind, parallel-group, phase 1 clinical trial comparing the pharmacokinetic, safety, and immunogenicity of the biosimilar hs016 and the originator adalimumab in Chinese healthy male subjects. Clin Pharmacol Drug Dev. 2021;10(3):317–325.
   PubMed Web of Science ®Google Scholar
• Liu Y, Yang G, Zhang J, et al. Anti-TNF-α monoclonal antibody reverses psoriasis through dual inhibition of inflammation and angiogenesis. Int Immunopharmacol. 2015;28(1):731–743.
   PubMed Web of Science ®Google Scholar
• Zhang H, Wu M, Sun J, et al. Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: results of a randomized, double-blind, parallel-controlled, phase 1 study. Pharmacol Res Perspect. 2021;9(2):e00733.
   PubMed Web of Science ®Google Scholar
• Lin J. BIO THERA SOLUTIONS LTD,assignee; Human antibody preparation for treating TNF (tumour necrosis factor)-alpha related diseases. China patent CN201310093009.7. 2013.
   Google Scholar
• Wu Y. BIO THERA SOLUTIONS LTD,assignee; Human antibody preparation for targeted therapy of TNF-alpha related diseases. China patent CN201910585391.0. 2019
   Google Scholar
• Leng CS. TONGHUA DONGBAO BIOLOGICAL TECH CO LTD,assignee; Combined medium for expressing Adalimumab. China patent CN201710981104.9. 2018
   Google Scholar
• Xie YL. CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD,assignee; Production method of anti-TNF-alpha monoclonal antibody. China patent CN201911005798.8. 2020
   Google Scholar
• Zhang ZB. SUZHOU ZHONGHE BIOMEDICAL TECH CO LTD,assignee; Method for detecting ethanol residue in recombinant hominine anti-TNF-a project cleaning validation sample. China patent CN201910038495.X. 2019;
   Google Scholar
• Apte RS, Chen DS, Ferrara N, et al. VEGF in signaling and disease: beyond discovery and development. Cell. 2019;176(6):1248–1264.
   PubMed Web of Science ®Google Scholar
• Hegde PS, Wallin JJ, Mancao C, et al. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. Semin Cancer Biol. 2018;52:117–124.
   PubMed Web of Science ®Google Scholar
• Sene A, Chin-Yee D, Apte RS, et al. Seeing through VEGF: innate and adaptive immunity in pathological angiogenesis in the eye. Trends Mol Med. 2015;21(1):43–51.
   PubMed Web of Science ®Google Scholar
• Liu YN, Huang J, Guo C, et al. A randomized, double-blind, single-dose study to evaluate the biosimilarity of QL1101 with bevacizumab in healthy male subjects. Cancer Chemother Pharmacol. 2020;85(3):555–562.
   PubMed Web of Science ®Google Scholar
• Chu T, Lu J, Bi M, et al. Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial. Cancer Biol Med. 2021;18(3). 10.20892/j.2095-3941.2020.0212
   PubMed Web of Science ®Google Scholar
• Zhang H. A phase I, randomized, double-blinded, single-dose study evaluating the pharmacokinetic equivalence of the biosimilar IBI305 and bevacizumab in healthy male subjects
Int. J Clin Pharmacol Ther. 2019;57: 167–174.
   Google Scholar
• Yang Y, Wu B, Huang L, et al. Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer. Transl Lung Cancer Res. 2019;8(6):989–999.
   PubMed Web of Science ®Google Scholar
• Duan X, Zhang H, Zhou L, et al. Complete response to the combination of sintilimab and IBI305 for a patient with HBV-associated hepatocellular carcinoma with multiple lung metastasis. Dig Liver Dis. 2020;52(7):794–796.
   PubMedGoogle Scholar
• Wu XY. Bio thera solutions LTD,assignee; High-stability humanized antibody preparation for treating VEGF related diseases. China patent CN201410198778.8. 2015
   Google Scholar
• Wang YJ. INNOVENT BIOLOG INC,assignee; Stable anti-VEGF antibody preparation and application thereof. China patent CN201410757524.5. 2015
   Google Scholar
• Cheng YJ. Chia tai tianqing pharmaceutical group co LTD,assignee; Pharmaceutical composition of humanized antibody for vascular endothelial growth factor. China patent CN201410487742.1. 2016
   Google Scholar
• Liu N. Shandong quangang pharmaceutical co LTD,assignee; method for purifying and preparing anti-VEGF antibody fragment. China patent CN201210185573.7. 2012
   Google Scholar
• Liu PP. Shanghai Cp Guojian Pharmaceutical Co LTD,assignee; Biological activity detection method for VEGF targeted therapy drugs. China patent CN201410625267. 2016
   Google Scholar
• Li QL. UNIV ANHUI,assignee; High-producing strain with capability of efficient secretion expression of anti-VEGF-Fab antibody fragment, and construction method thereof. China patent CN201810364192.2. 2018
   Google Scholar
• Raje NS, Bhatta S, Terpos E, et al. Role of the RANK/RANKL pathway in multiple myeloma. Clin Cancer Res. 2019;25(1):12–20.
   PubMed Web of Science ®Google Scholar
• Honma M, Ikebuchi Y, Suzuki H, et al. RANKL as a key figure in bridging between the bone and immune system: its physiological functions and potential as a pharmacological target. Pharmacol Ther. 2021;218:107682.
   PubMed Web of Science ®Google Scholar
• Tan W, Zhang W, Strasner A, et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature. 2011;470(7335):548–553.
   PubMed Web of Science ®Google Scholar
• Lorenzo J. The many ways of osteoclast activation. J Clin Invest. 2017;127(7):2530–2532.
   PubMed Web of Science ®Google Scholar
• Tsai JN, Uihlein AV, Lee H, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet. 2013;382(9886):50–56.
   PubMed Web of Science ®Google Scholar
• Smith MR, Egerdie B, Toriz NH, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361(8):745–755.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813–822.
   PubMed Web of Science ®Google Scholar
• Cummings SR, Martin JS, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–765.
   PubMed Web of Science ®Google Scholar
• Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513–523.
   PubMed Web of Science ®Google Scholar
• Mei F. MABWELL SHANGHAI BIOSCIENCE CO LTD,assignee; Disulfide bond isomer of recombinant anti-RANKL antibody IgG2 type and purification method of disulfide bond isomer. China patent CN202010828720.2. 2020
   Google Scholar
• Liu PP. Sunshine Guojian Pharmaceutical Shanghai CO LTD,assignee; Method for detecting biological activity of RANKL (receptor activator for nuclear factor-kappa B ligand) targeted therapeutic drug. China patent CN201610859356.X. 2018;
   Google Scholar
• Ye CG, Xu P, Cai W-J, et al. AMPO BIOTECHNOLOGY INC,assignee; Method for detecting biological activity of RANKL (receptor activator for nuclear factor-KB ligands) targeted therapy medicines. BMC Cancer. 2018 China patent CN201810642794.X; 186: 10.1186/s12885-018-4349-y
   Google Scholar
• Ding MS. JIANGSU T MAB BIOPHARMA CO LTD,assignee; In vitro test tool and method for evaluating biological activity of RANKL target spot compound. China patent CN201810743674.9. 2018
   Google Scholar
• Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22(47):7359–7368.
   PubMed Web of Science ®Google Scholar
• Shanehbandi D, Majidi J, Kazemi T, et al. CD20-based immunotherapy of b-cell derived hematologic malignancies. Curr Cancer Drug Targets. 2017;17(5):423–444.
   PubMed Web of Science ®Google Scholar
• Al-Naeeb A B Non-Hodgkin lymphoma. Bmj. 2018;362:k3204.
   PubMedGoogle Scholar
• Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127(2):208–215.
   PubMed Web of Science ®Google Scholar
• Hallek M, Shanafelt TD, Eichhorst B, et al. Chronic lymphocytic leukaemia. Lancet. 2018;391(10129):1524–1537.
   PubMed Web of Science ®Google Scholar
• Liu YJ.2020. Shanghai Pharmaceuticals Holding Co Ltd,assignee; Medicine preparation containing anti-CD20 antibody as well as preparation method and application of medicine preparation. China patent CN201911157456.8.
   Google Scholar
• Song H. Shanghai Hankang Bio Pharmaceutical Technology CO LTD,assignee; Anti-CD20 monoclonal antibody, preparation method and application thereof. China patent CN201210356034.5. 2013
   Google Scholar
• Shen BB. ZHEJIANG TERUISI PHARMACEUTICAL INC,assignee; High-expression and high-stability CHO cell line for producing Rituximab and constructing method thereof. China patent CN201710087562.8. 2018
   Google Scholar
• Zhang GM. Lunan Pharmaceutical group corp,assignee; method for purifying anti-CD20 human-mouse chimeric monoclonal antibody. China patent CN201810135774.3. 2019
   Google Scholar
• Liu PP. GENOR BIOPHARMA CO LTD,assignee; Detection method for anti-CD20 monoclonal antibody binding activities. China patent CN201110302889.5. 2013
   Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127–137.
   PubMed Web of Science ®Google Scholar
• Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007;26:6469–6487.
   PubMed Web of Science ®Google Scholar
• Gutierrez C, Schiff R. HER2: biology, detection, and clinical implications. Arch Pathol Lab Med. 2011;135(1):55–62.
   PubMed Web of Science ®Google Scholar
• Oh DY, Bang YJ. HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17(1):33–48.
   PubMed Web of Science ®Google Scholar
• Loibl S, Gianni L. HER2-positive breast cancer. Lancet. 2017;389(10087):2415–2429.
   PubMed Web of Science ®Google Scholar
• Swain SM, Miles D, Kim S-B, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(4):519–530.
   PubMed Web of Science ®Google Scholar
• Swain SM, Baselga J, Kim S-B, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724–734.
   PubMed Web of Science ®Google Scholar
• Hurvitz SA, Martin M, Symmans WF, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2018;19(1):115–126.
   PubMed Web of Science ®Google Scholar
• Baselga J, Cortés J, Kim S-B, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109–119.
   PubMed Web of Science ®Google Scholar
• Zhu X, Ding Y, Yu Y, et al. A Phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX02 to reference CN- and EU-sourced trastuzumab in healthy subjects. Cancer Chemother Pharmacol. 2021;87(3):349–359.
   PubMed Web of Science ®Google Scholar
• Xu B, Zhang Q, Sun T, et al. Efficacy, safety, and immunogenicity of hlx02 compared with reference trastuzumab in patients with recurrent or metastatic HER2-positive breast cancer: a randomized phase iii equivalence trial. BioDrugs. 2021;35(3):337–350.
   PubMed Web of Science ®Google Scholar
• Wang H. SHANGHAI ZHONGJIAN BIOTECHNOLO,assignee; Stable anti-HER2 humanized antibody preparation. China patent CN200610147280.4. 2008
   Google Scholar
• Ma CJ. SHANGHAI HENLIUS BIOTECH INC,assignee; Pharmaceutical preparation containing anti-Her2 monoclonal antibody. China patent CN201811628635.0. 2020
   Google Scholar
• Wu TT. Jiangsu hengrui medicine co;shanghai hengrui pharmaceutical co ltd,assignee; HER2 antibody pharmaceutical composition and application thereof. China patent CN201910643662.3. 2020
   Google Scholar
• Xu ZH. GENOR BIOPHARMA CO LTD,assignee; Method for purifying anti-HER2 or/and anti-HER3 antibody proteins. China patent CN201110452837.6. 2012
   Google Scholar
• Li L. SHENZHEN Main Luck Pharmaceuticals Inc,assignee; Purification method of monoclonal antibodies. China patent CN201610901017.3. 2017
   Google Scholar
• Xie YL. Chia tai tianqing pharmaceutical group nanjing shunxin pharmaceutical co ltd;chia tai tianqing pharmaceutical group co ltd,assignee; Purification method of anti-HER2 monoclonal antibody. China patent CN201911191084.0. 2020
   Google Scholar
• Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008;358(11):1160–1174.
   PubMed Web of Science ®Google Scholar
• Wee P, Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (Basel). 2017;9:52.
   PubMed Web of Science ®Google Scholar
• Degirmenci U, Wang M, Hu J, et al. Targeting Aberrant RAS/RAF/MEK/ERK signaling for cancer therapy. Cells. 2020;9(1):198.
   PubMed Web of Science ®Google Scholar
• He WH. AMPO BIOTECHNOLOGY CO LTD,assignee; Detection method for biological activity of anti-EGFR monoclonal antibodies. China patent CN201410840995.2. 2015
   Google Scholar
• Qian WZI SHANGHAI ZHANGJIANG BIOTECHNOLOGY CO LTD assignee; Method for preparing novel anti-EGFR monoclonal antibody and application thereof. China patent CN201510006233.7. 2016
   Google Scholar
• Yu HY, et al. Beijing sl pharmaceutical co ltd;beijing sl lisheng medical tech co ltd;beijing shuanglu biological tech co ltd,assignee; Screening culture method of cells capable of efficiently expressing anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody. China patent CN202011192793.3. 2021
   Google Scholar
• van de Donk N, van de Donk NWCJ, Richardson PG, et al. CD38 antibodies in multiple myeloma: back to the future. Blood. 2018;131:13–29.
   PubMed Web of Science ®Google Scholar
• Chen L, Diao L, Yang Y, et al. CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade. Cancer Discov. 2018;8(9):1156–1175.
   PubMed Web of Science ®Google Scholar
• Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018;18(3):153–167.
   PubMed Web of Science ®Google Scholar
• Rowshanravan B, Halliday N, Sansom DM, et al. CTLA-4: a moving target in immunotherapy. Blood. 2018;131(1):58–67.
   PubMed Web of Science ®Google Scholar
• Mitsuiki N, Schwab C, Grimbacher B, et al. What did we learn from CTLA-4 insufficiency on the human immune system? Immunol Rev. 2019;287(1):33–49.
   PubMed Web of Science ®Google Scholar
• Xiao H. SHANGHAI HENLIUS BIOTECH CO LTD,assignee; Anti-CTLA-4 humanized antibody. China patent CN201410838544.5. 2015
   Google Scholar
• Bai Y. Beijing Dongfang Biotech Co Ltd,assignee; Injection preparation of anti-CTLA-4 monoclonal antibody. China patent CN201911022188.9. 2020
   Google Scholar
• Fang GB. Shanghai Celgen Biopharma Co LtD,assignee; Anti-CTLA-4 antibody and fusion protein preparation. China patent CN202011462549.4. 2021 Mar
   Google Scholar
• McGregor MC, Krings JG, Nair P, et al. Role of Biologics in Asthma. Am J Respir Crit Care Med. 2019;199(4):433–445.
   PubMed Web of Science ®Google Scholar
• Chen SK. PKU UNIV V-MING (HEFEI) BIOLOGICS CO LTD,assignee; Arginine-based method for preventing aggregation of omalizumab. China patent CN201910977910.8. 2020
   Google Scholar
• Wang SX. Shanghai Mab Venture Biological Pharmaceutical CO LTD,assignee; Method for detecting hydrophobicity of Omalizumab. China patent CN201911423842.7. 2020
   Google Scholar
• Wang SX. Shanghai Mab Venture Biological Pharmaceutical Co Ltd, assignee; Separation method of charge heteroplasmon of omalizumab. China patent CN201911417917.0. 2020
   Google Scholar
• Tait Wojno ED, Hunter CA, Stumhofer JS, et al. The immunobiology of the interleukin-12 family: room for discovery. Immunity. 2019;50(4):851–870.
   PubMed Web of Science ®Google Scholar
• Kishimoto T. The biology of interleukin-6. Blood. 1989;74(1):1–10.
   PubMed Web of Science ®Google Scholar
• Iwakura Y, Ishigame H, Saijo S, et al. Functional specialization of interleukin-17 family members. Immunity. 2011;34(2):149–162.
   PubMed Web of Science ®Google Scholar
• Lin J. Bio-thera solutions ltd assignee; Liquid preparation of humanized antibody for treating IL-6 related diseases. China patent CN202010129494.9. 2020
   Google Scholar
• Ouyang ZY. Mabwell shanghai bioscience co ltD,assignee; Method for removing cysteinylated variant from secukinumab product. China patent CN201910029571.0. 2019
   Google Scholar
• Sarpatwari A, Barenie R, Curfman G, et al. The US biosimilar market: stunted growth and possible reforms. Clin Pharmacol Ther. 2019;105(1):92–100.
   PubMed Web of Science ®Google Scholar
• Iwamoto N. Antibody drug quantitation in coexistence with anti-drug antibodies on nSMOL bioanalysis. Anal Biochem. 2018;540-541:30–37.
   PubMed Web of Science ®Google Scholar
• Zhang H, Li Q, Zhu X, et al. Tolerance, variability, and pharmacokinetics of bevacizumab biosimilars in Chinese healthy male subjects. Cancer Chemother Pharmacol. 2018;82(4):615–623.
   PubMed Web of Science ®Google Scholar
• Zhang E, Xie L, Qin P, et al. Quality by design-based assessment for analytical similarity of adalimumab biosimilar HLX03 to Humira®. Aaps j. 2020;22(3):69.
   PubMed Web of Science ®Google Scholar
• NMPA. Decree of the state food and drug administration no. 2022. http://www.gov.cn/gongbao/content/2008/content_934084.htm
   Google Scholar
• NMPA. Implementing regulations of the drug administration law of the PRC (Draft amendment for solicitation of comments). 2022.https://www.nmpa.gov.cn/xxgk/zhqyj/zhqyjyp/20220509220456183.htm
   Google Scholar